CymaBay Therapeutics Stock Forecast, Price & News

+0.04 (+0.95 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $4.23
50-Day Range
MA: $4.73
52-Week Range
Now: $4.23
Volume835,083 shs
Average Volume1.14 million shs
Market Capitalization$291.64 million
P/E RatioN/A
Dividend YieldN/A
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
CymaBay Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CBAY
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$2.71 per share


Net Income$-102,810,000.00


Market Cap$291.64 million
Next Earnings Date5/10/2021 (Estimated)


CBAY Apr 2021 9.000 call
April 8, 2021 |
CBAY Oct 2021 10.000 call
April 7, 2021 |
CymaBay Therapeutics (NASDAQ:CBAY) Price Target Cut to $7.00
March 31, 2021 |
Is CBAY A Good Stock To Buy Now?
December 16, 2020 |
See More Headlines


Overall MarketRank

1.64 out of 5 stars

Medical Sector

342nd out of 2,019 stocks

Pharmaceutical Preparations Industry

155th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.04 (+0.95 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

Is CymaBay Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CymaBay Therapeutics?

Wall Street analysts have given CymaBay Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CymaBay Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a increase in short interest during the month of February. As of February 26th, there was short interest totaling 8,340,000 shares, an increase of 22.3% from the February 11th total of 6,820,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is presently 6.6 days. Currently, 13.1% of the company's shares are sold short.
View CymaBay Therapeutics' Short Interest

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for CymaBay Therapeutics

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its earnings results on Wednesday, March, 24th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.03.
View CymaBay Therapeutics' earnings history

How has CymaBay Therapeutics' stock price been impacted by Coronavirus?

CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CBAY stock has increased by 174.7% and is now trading at $4.23.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CBAY?

12 brokers have issued 1 year target prices for CymaBay Therapeutics' stock. Their forecasts range from $7.00 to $15.00. On average, they expect CymaBay Therapeutics' share price to reach $11.77 in the next twelve months. This suggests a possible upside of 178.2% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 48, Pay $667.35k)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 66, Pay $514.65k)
  • Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 53, Pay $441.84k)
  • Mr. Daniel Menold, VP of Fin. (Age 51)
  • Mr. Paul T. Quinlan, Gen. Counsel (Age 58)
  • Mr. Ken Boehm, Sr. VP of HR
  • Mr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 60)
  • Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 59)
  • Ms. Becki Filice, Sr. VP of Portfolio & Product Leadership (Age 60)

Who are some of CymaBay Therapeutics' key competitors?

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $4.23.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics has a market capitalization of $291.64 million. The biopharmaceutical company earns $-102,810,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does CymaBay Therapeutics have?

CymaBay Therapeutics employs 36 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is

Where are CymaBay Therapeutics' headquarters?

CymaBay Therapeutics is headquartered at 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]

This page was last updated on 4/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.